Cancer Causes & Control

, Volume 25, Issue 12, pp 1587–1593 | Cite as

Urinary bisphenol A-glucuronide and postmenopausal breast cancer in Poland

  • Britton TrabertEmail author
  • Roni T. Falk
  • Jonine D. Figueroa
  • Barry I. Graubard
  • Montserrat Garcia-Closas
  • Jolanta Lissowska
  • Beata Peplonska
  • Stephen D. Fox
  • Louise A. Brinton
Original paper



Concerns regarding a possible link between bisphenol A (BPA) and breast cancer have been mounting, but studies in human populations are lacking. We evaluated the association between the major urinary BPA metabolite [BPA-glucuronide (BPA-G)] and postmenopausal breast cancer risk in a large population-based case–control study conducted in two cities in Poland (2000–2003); we further explored the association of BPA-G levels with known postmenopausal breast cancer risk factors in our control population.


We analyzed creatinine-adjusted urinary BPA-G levels among 575 postmenopausal cases matched on age and study site to 575 controls without breast cancer using a recently developed assay. Odds ratios and 95 % confidence intervals were used to estimate the association between urinary BPA-G level and breast cancer using conditional logistic regression. Among controls, geometric mean BPA-G levels were compared across categories of breast cancer risk factors using linear regression models.


There was no indication that increased BPA-G was associated with postmenopausal breast cancer (p-trend = 0.59). Among controls, mean BPA-G was higher among women reporting extended use of menopausal hormones, a prior screening mammogram, and residence in Warsaw. Other comparisons across strata of postmenopausal breast cancer risk factors were not related to differences in BPA-G.


Urinary BPA-G, measured at the time of diagnosis, is not linked to postmenopausal breast cancer.


Breast cancer Bisphenol A-glucuronide Postmenopausal Case–control 



This research was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

Conflict of interest

The authors declare that they have no actual or potential competing financial interests.

Supplementary material

10552_2014_461_MOESM1_ESM.pdf (27 kb)
Supplementary material 1 (PDF 27 kb)
10552_2014_461_MOESM2_ESM.pdf (26 kb)
Supplementary material 2 (PDF 27 kb)
10552_2014_461_MOESM3_ESM.pdf (908 kb)
Supplementary material 3 (PDF 909 kb)


  1. 1.
    Talsness CE, Andrade AJ, Kuriyama SN, Taylor JA, vom Saal FS (2009) Components of plastic: experimental studies in animals and relevance for human health. Philos Trans R Soc Lond B Biol Sci 364(1526):2079–2096. doi: 10.1098/rstb.2008.0281 PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Stahlhut RW, Welshons WV, Swan SH (2009) Bisphenol A data in NHANES suggest longer than expected half-life, substantial nonfood exposure, or both. Environ Health Perspect 117(5):784–789. doi: 10.1289/ehp.0800376 PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Durando M, Kass L, Perdomo V, Bosquiazzo VL, Luque EH, Munoz-de-Toro M (2011) Prenatal exposure to bisphenol A promotes angiogenesis and alters steroid-mediated responses in the mammary glands of cycling rats. J Steroid Biochem Mol Biol 127(1–2):35–43. doi: 10.1016/j.jsbmb.2011.04.001 PubMedCrossRefGoogle Scholar
  4. 4.
    Durando M, Kass L, Piva J et al (2007) Prenatal bisphenol A exposure induces preneoplastic lesions in the mammary gland in Wistar rats. Environ Health Perspect 115(1):80–86PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Tharp AP, Maffini MV, Hunt PA, Vandevoort CA, Sonnenschein C, Soto AM (2012) Bisphenol A alters the development of the rhesus monkey mammary gland. Proc Natl Acad Sci USA 109(21):8190–8195. doi: 10.1073/pnas.1120488109 PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Dairkee SH, Seok J, Champion S et al (2008) Bisphenol A induces a profile of tumor aggressiveness in high-risk cells from breast cancer patients. Cancer Res 68(7):2076–2080. doi: 10.1158/0008-5472 PubMedCrossRefGoogle Scholar
  7. 7.
    Recchia AG, Vivacqua A, Gabriele S et al (2004) Xenoestrogens and the induction of proliferative effects in breast cancer cells via direct activation of oestrogen receptor alpha. Food Addit Contam 21(2):134–144. doi: 10.1080/02652030310001641177 PubMedCrossRefGoogle Scholar
  8. 8.
    Vivacqua A, Recchia AG, Fasanella G et al (2003) The food contaminants bisphenol A and 4-nonylphenol act as agonists for estrogen receptor alpha in MCF7 breast cancer cells. Endocrine 22(3):275–284. doi: 10.1385/ENDO:22:3:275 PubMedCrossRefGoogle Scholar
  9. 9.
    Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Ekong J, Needham LL (2005) Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environ Health Perspect 113(4):391–395PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL (2008) Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003–2004. Environ Health Perspect 116(1):39–44. doi: 10.1289/ehp.10753 PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV (2007) Human exposure to bisphenol A (BPA). Reprod Toxicol 24(2):139–177. doi: 10.1016/j.reprotox.2007.07.010 PubMedCrossRefGoogle Scholar
  12. 12.
    Melzer D, Rice NE, Lewis C, Henley WE, Galloway TS (2010) Association of urinary bisphenol a concentration with heart disease: evidence from NHANES 2003/06. PLoS One 5(1):e8673. doi: 10.1371/journal.pone.0008673 PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Carwile JL, Michels KB (2011) Urinary bisphenol A and obesity: NHANES 2003–2006. Environ Res 111(6):825–830. doi: 10.1016/j.envres.2011.05.014 PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Yang M, Ryu JH, Jeon R, Kang D, Yoo KY (2009) Effects of bisphenol A on breast cancer and its risk factors. Arch Toxicol 83(3):281–285. doi: 10.1007/s00204-008-0364-0 PubMedCrossRefGoogle Scholar
  15. 15.
    Volkel W, Colnot T, Csanady GA, Filser JG, Dekant W (2002) Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chem Res Toxicol 15(10):1281–1287PubMedCrossRefGoogle Scholar
  16. 16.
    Garcia-Closas M, Brinton LA, Lissowska J et al (2006) Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 95(1):123–129. doi: 10.1038/sj.bjc.6603207 PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Fox SD, Falk RT, Veenstra TD, Issaq HJ (2011) Quantitation of free and total bisphenol A in human urine using liquid chromatography-tandem mass spectrometry. J Sep Sci 34(11):1268–1274. doi: 10.1002/jssc.201100087 PubMedCrossRefGoogle Scholar
  18. 18.
    Nachman RM, Fox SD, Golden WC et al (2013) Urinary free bisphenol A and bisphenol A-glucuronide concentrations in newborns. J Pediatr 162(4):870–872. doi: 10.1016/j.jpeds.2012.11.083 PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Calafat AM, Koch HM, Swan SH et al (2013) Misuse of blood serum to assess exposure to bisphenol A and phthalates. Breast Cancer Res 15(5):403. doi: 10.1186/bcr3494 PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Harthe C, Rinaldi S, Achaintre D et al (2012) Bisphenol A-glucuronide measurement in urine samples. Talanta 100:410–413. doi: 10.1016/j.talanta.2012.07.099 PubMedCrossRefGoogle Scholar
  21. 21.
    Lang IA, Galloway TS, Scarlett A et al (2008) Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 300(11):1303–1310. doi: 10.1001/jama.300.11.1303 PubMedCrossRefGoogle Scholar
  22. 22.
    Melzer D, Osborne NJ, Henley WE et al (2012) Urinary bisphenol A concentration and risk of future coronary artery disease in apparently healthy men and women. Circulation 125(12):1482–1490. doi: 10.1161/CIRCULATIONAHA.111.069153 PubMedCrossRefGoogle Scholar
  23. 23.
    Wang T, Li M, Chen B et al (2012) Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metab 97(2):E223–E227. doi: 10.1210/jc.2011-1989 PubMedCrossRefGoogle Scholar
  24. 24.
    Sprague BL, Trentham-Dietz A, Hedman CJ et al (2013) Circulating serum xenoestrogens and mammographic breast density. Breast Cancer Res 15(3):R45. doi: 10.1186/bcr3432 PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Townsend MK, Franke AA, Li X et al (2013) Within-person reproducibility of urinary bisphenol A and phthalate metabolites over a 1–3 year period among women in the Nurses’ Health Studies: a prospective cohort study. Environ Health 12(1):80. doi: 10.1186/1476-069X-12-80 PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Braun JM, Kalkbrenner AE, Calafat AM et al (2011) Variability and predictors of urinary bisphenol A concentrations during pregnancy. Environ Health Perspect 119(10):131–137. doi: 10.1289/ehp.1002366 PubMedCentralPubMedGoogle Scholar
  27. 27.
    Ye X, Wong LY, Bishop AM, Calafat AM (2011) Variability of urinary concentrations of bisphenol A in spot samples, first morning voids, and 24-h collections. Environ Health Perspect 119(7):983–988. doi: 10.1289/ehp.1002701 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland (outside the USA) 2014

Authors and Affiliations

  • Britton Trabert
    • 1
    Email author
  • Roni T. Falk
    • 1
  • Jonine D. Figueroa
    • 1
  • Barry I. Graubard
    • 1
  • Montserrat Garcia-Closas
    • 2
  • Jolanta Lissowska
    • 3
  • Beata Peplonska
    • 4
  • Stephen D. Fox
    • 5
  • Louise A. Brinton
    • 1
  1. 1.Division of Cancer Epidemiology and Genetics, Department of Health and Human ServicesNational Cancer Institute, National Institutes of HealthBethesdaUSA
  2. 2.The Institute of Cancer ResearchLondonUK
  3. 3.Department of Cancer Epidemiology and PreventionCancer Center and M. Sklodowska-Curie Institute of OncologyWarsawPoland
  4. 4.Department of Environmental EpidemiologyNofer Institute of Occupational MedicineLodzPoland
  5. 5.Protein Characterization Laboratory, Cancer Research Technology ProgramLeidos Biomedical Research, Inc., Frederick National Laboratory for Cancer ResearchFrederickUSA

Personalised recommendations